GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 11
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. 12126-12126
    Abstract: 12126 Background: The study was to evaluate the equivalence of LY01011 to the reference product denosumab in terms of reduction of bone metabolism markers. Methods: Eligible patients were randomized at 1:1 ratio to receive 120 mg LY01011 injection or 120 mg denosumab every four weeks subcutaneously. Following the completion of three doses of 120 mg LY01011 or denosumab in a 12-week double-blind treatment period (DBTP), all enrolled patients would continue to receive LY01011 administration until the week 53 of follow-up period. The primary end point was the natural logarithm change at week 13 from baseline in urinary cross-linked N terminal telopeptide of type I collagen, corrected for urine creatinine (uNTx/uCr). The equivalence between LY01011 and denosumab would be concluded if the 90% CI was completely inside the pre-defined equivalence boundary between -0.135 and 0.135. A formal blinded sample-size re-estimation (BSSR) was planned to take place once 60% of the planned participants had completed the Week 13 assessments. After BSSR, the sample size increased from 560 to 850 according to prespecified procedure based on pooled standard deviationfrom the blinded data, which was set as a cap to ensure a feasible sample size for the study and no need to do any multiplicity adjustment. Results: All eligible 850 patients, included in the full analysis set, were randomized into the LY01011 group (n = 424) and denosumab group (n = 426). The samples from the 12-week DBTP were collected for analysis in both groups. The least square mean (LSM) (SE) of the natural logarithm change of uNTX/uCr at week 13 from baseline was -1.740 (0.0420) in the LY01011 group and -1.745 (0.0421) in denosumab group. The LSM difference was 0.005 between LY01011 and denosumab groups with 90% CI of [-0.088, 0.097] (p 〉 0.05). Skeletal related events occurring in the LY01011 and denosumab groups were 3.5% and 2.8%, respectively. The mean (SD) percentage changes of serum bone-specific alkaline phosphatase (s-BALP) from baseline to week 13 were -31.154% (39.6790) and -33.021% (37.3826) in the LY01011 and denosumab groups, respectively. The median was -36.866% and -37.457% (p 〉 0.05). The incidence of treatment-emergent adverse events (TEAEs) of any grade was 91.7% and 90.8% in LY01011 and denosumab groups(p 〉 0.05). Both groups had 38.4% of Grade ≥3 TEAEs, of which 5.4% (LY01011) and 4.5% (denosumab) were judged to be related to the study drug. Immunogenicity analysis showed that no participant (0/399) had a positive ADA test in denosumab group and only one participant (0.2%, 1/401) was tested ADA positive in LY01011 group. Conclusions: The study demonstrated the equivalent efficacy of LY01011 in the reduction of bone metabolism biomarker NTX to reference product, denosumab, which met the primary endpoint. It had a good safety profile with no unexpected adverse reactions in the study. Clinical trial information: NCT04859569 .
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 12
    Online Resource
    Online Resource
    Elsevier BV ; 2016
    In:  Wear Vol. 364-365 ( 2016-10), p. 233-243
    In: Wear, Elsevier BV, Vol. 364-365 ( 2016-10), p. 233-243
    Type of Medium: Online Resource
    ISSN: 0043-1648
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2016
    detail.hit.zdb_id: 1501123-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 13
    Online Resource
    Online Resource
    Elsevier BV ; 2011
    In:  Wear Vol. 271, No. 9-10 ( 2011-7), p. 2433-2437
    In: Wear, Elsevier BV, Vol. 271, No. 9-10 ( 2011-7), p. 2433-2437
    Type of Medium: Online Resource
    ISSN: 0043-1648
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2011
    detail.hit.zdb_id: 1501123-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 14
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2021
    In:  International Journal of Precision Engineering and Manufacturing Vol. 22, No. 1 ( 2021-01), p. 1-12
    In: International Journal of Precision Engineering and Manufacturing, Springer Science and Business Media LLC, Vol. 22, No. 1 ( 2021-01), p. 1-12
    Type of Medium: Online Resource
    ISSN: 2234-7593 , 2005-4602
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 2515436-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 15
    In: Frontiers in Veterinary Science, Frontiers Media SA, Vol. 9 ( 2022-6-15)
    Abstract: 11S glycinin is a major soybean antigenic protein, which induces human and animal allergies. It has been reported to induce intestinal porcine epithelial (IPEC-J2) cell apoptosis, but the role of pyroptosis in 11S glycinin allergies remains unknown. In this study, IPEC-J2 cells were used as an in vitro physiological model to explore the mechanism of 11S glycinin-induced pyroptosis. The cells were incubated with 0, 1, 5, and 10 mg·ml −1 11S glycinin for 24 h. Our results revealed that 11S glycinin significantly inhibited cell proliferation, induced DNA damage, generated active oxygen, decreased mitochondrial membrane potential, and increased the NOD-like receptor protein 3 (NLRP-3) expression of IPEC-J2 cells in a dose-dependent manner. Further, IPEC-J2 cells were transfected with designed sh-NLRP-3 lentivirus to silence NLRP-3 . The results showed that 11S glycinin up-regulated the silenced NLRP-3 gene and increased the expression levels of apoptosis-related spot-like protein (ASC), caspase-1, the cleaved gasdermin D, and interleukin-1β. The IPEC-J2 cells showed pyrolysis morphology. Moreover, we revealed that N-acetyl-L-cysteine can significantly inhibit the production of reactive oxygen species and reduce the expression levels of NLRP-3 and the cleaved gasdermin D. Taken together, 11S glycinin up-regulated NLRP-3-induced pyroptosis by triggering reactive oxygen species in IPEC-J2 cells.
    Type of Medium: Online Resource
    ISSN: 2297-1769
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2022
    detail.hit.zdb_id: 2834243-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 16
    In: EBioMedicine, Elsevier BV, Vol. 65 ( 2021-03), p. 103251-
    Type of Medium: Online Resource
    ISSN: 2352-3964
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 2799017-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 17
    Online Resource
    Online Resource
    Institute of Electrical and Electronics Engineers (IEEE) ; 2019
    In:  IEEE Access Vol. 7 ( 2019), p. 105514-105530
    In: IEEE Access, Institute of Electrical and Electronics Engineers (IEEE), Vol. 7 ( 2019), p. 105514-105530
    Type of Medium: Online Resource
    ISSN: 2169-3536
    Language: Unknown
    Publisher: Institute of Electrical and Electronics Engineers (IEEE)
    Publication Date: 2019
    detail.hit.zdb_id: 2687964-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 18
    In: Journal for ImmunoTherapy of Cancer, BMJ, Vol. 10, No. 3 ( 2022-03), p. e003477-
    Abstract: Epidemiological surveys have revealed that low serum vitamin D level was correlated with increased risk of tumors. Dysfunctional T cells in patients with tumor are characterized as exhausted with high levels of immune checkpoint receptors (ICRs). However, whether the reduced level of vitamin D in patients with cancer correlates with cytotoxic T-cell exhaustion is unknown. Methods Periphery blood samples from 172 patients with non-small cell lung cancer (NSCLC) were prospectively collected. Patients with NSCLC received one course of intravenous docetaxel (75 mg/m 2 ) followed by treatment with or without rocaltrol at a dose of 0.5–2.0 µg/day for total of 3 weeks. We performed phenotypical and functional analysis of T-cell through flow cytometry. Vitamin D receptor (VDR) knockout and overexpression CD8 + and Vδ2 + T cells were constructed using Cas9-gRNA targeted and overexpressing approaches to identify 1α,25(OH) 2 D 3 /VDR-mediated transcription regulation for ICRs or antitumor activity in T cells. Results We show that serum level of vitamin D is negatively correlated with expression of programmed cell death-1 (PD-1), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and T-cell immunoglobulin and mucin-domain containing-3 (Tim-3), but positively correlated with CD28 expression on CD8 + and Vγ9Vδ2 + T cells in patients with NSCLC. 1α,25(OH) 2 D 3 , the active form of vitamin D, promotes the nuclear translocation of VDR, which binds to the promoter region of Pdcd1 , Tim3 , and Tigit genes and inhibits their expression. Besides, 1α,25(OH) 2 D 3 pretreatment also promotes the methylation of CpG island in the promoter region of the Pdcd1 gene and increases H3K27 acetylation at the promoter region of the Cd28 gene, which leads to surface PD-1 downregulation and CD28 upregulation, respectively. We further reveal that VDR-mediated Ca 2+ influx enhanced expression of Th1 cytokines via T-cell receptor activation. Functionally, 1α,25(OH) 2 D 3 pretreated CD8 + T cells or Vγ9Vδ2 + T cells showed increased Th1 cytokine production and enhanced antitumor immunity. Finally, oral 1α,25(OH) 2 D 3 could also decrease expression of PD-1, Tim-3, TIGIT and increase expression of CD28, resulting in cytokine production (associated with antitumor immunity) by cytotoxic T cells of patients with NSCLC. Conclusions Our findings uncover the pleiotropic effects of 1α,25(OH) 2 D 3 in rescuing the exhausted phenotype of human cytotoxic T cells in patients with tumor and in promoting their antitumor immunity. Trial registration number ChiCTR2100051135.
    Type of Medium: Online Resource
    ISSN: 2051-1426
    Language: English
    Publisher: BMJ
    Publication Date: 2022
    detail.hit.zdb_id: 2719863-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 19
    Online Resource
    Online Resource
    Frontiers Media SA ; 2021
    In:  Frontiers in Cell and Developmental Biology Vol. 9 ( 2021-7-2)
    In: Frontiers in Cell and Developmental Biology, Frontiers Media SA, Vol. 9 ( 2021-7-2)
    Abstract: Background: Immunotherapy elicits durable responses in many tumors. Nevertheless, the positive response to immunotherapy always depends on the dynamic interactions between the tumor cells and infiltrating lymphocytes in the tumor microenvironment (TME). Currently, the application of immunotherapy in hepatocellular carcinoma (HCC) has achieved limited success. The ectopic modification of N6-methyladenosine (m6A) is a common feature in multiple tumors. However, the relationship between m6A modification with HCC clinical features, prognosis, immune cell infiltration, and immunotherapy efficacy remains unclear. Materials and Methods: Here, we comprehensively evaluated m6A modification clusters based on 22 m6A regulators and systematically explored the relationship between m6A modification with tumor progression, prognosis, and immune cell infiltration characteristics. The m6Ascore was calculated by principal component analysis to quantify the m6A modifications of individual patients. Key regulators involved in immunoregulation in HCC were identified using immunohistochemistry and immunofluorescence. Results: Three distinct m6A modification clusters were identified. The m6A clusters were significantly associated with clinical features, prognosis, and immune cell infiltration. The three clusters were highly consistent with the three tumor immune phenotypes, i.e., immune-excluded, immune-inflamed, and immune-desert. Comprehensive bioinformatics analysis revealed that high m6Ascore was closely associated with tumor progression, poor prognosis, and immunotherapy non-response. m6A regulators were dysregulated in HCC tissues. Hence, they play a role as predictors of poor prognosis. Tissue microarray demonstrated that overexpressed YTHDF1 was associated with low CD3 + and CD8 + T cell infiltration in HCC. Conclusion: Our findings demonstrate that m6A modification patterns play a crucial role in the tumor immune microenvironment and the prognosis of HCC. High YTHDF1 expression is closely associated with low CD3 + and CD8 + T cell infiltration in HCC.
    Type of Medium: Online Resource
    ISSN: 2296-634X
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2021
    detail.hit.zdb_id: 2737824-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 20
    In: BMC Cancer, Springer Science and Business Media LLC, Vol. 11, No. 1 ( 2011-12)
    Abstract: Human epidermal growth factor receptor 2 (HER2) is the most crucial ErbB receptor tyrosine kinase (RTK) family member in HER2-positive (refered to HER2-overexpressing) breast cancer which are dependent on or "addictive" to the Phosphatidylinositol-3-kinase (PI3K) pathway. HER2-related target drugs trastuzumab and lapatinib have been the foundation of treatment of HER2--positive breast cancer. This study was designed to explore the relationship between PI3K pathway activation and the sensitivity to lapatinib in HER2--positive metastatic breast cancer patients pretreated with anthracyclins, taxanes and trastuzumab. Methods Sixty-seven HER2-positive metastatic breast cancer patients were recruited into a global lapatinib Expanded Access Program and 57 patients have primary tumor specimens available for determination of PI3K pathway status. PTEN status was determined by immunohistochemical staining and PIK3CA mutations were detected via PCR sequencing. All patients were treated with lapatinib 1250 mg/day continuously and capecitabine 1000 mg/m 2 twice daily on a 2-week-on and 1-week-off schedule until disease progression, death, withdrawal of informed consent, or intolerable toxicity. Results PIK3CA mutations and PTEN loss were detected in 12.3% (7/57) and 31.6% (18/57) of the patients, respectively. Twenty-two patients with PI3K pathway activation (defined as PIK3CA mutation and/or PTEN expression loss) had a lower clinical benefit rate (36.4% versus 68.6%, P = 0.017) and a lower overall response rate (9.1% versus 31.4%, P = 0.05), when compared with the 35 patients with no activation. A retrospective analysis of first trastuzumab-containing regimen treatment data showed that PI3K pathway activation correlated with a shorter median progression-free survival (4.5 versus 9.0 months, P = 0.013). Conclusions PIK3CA mutations occur more frequently in elder patients for HER2-positive breast cancer. PIK3CA mutations and PTEN loss are not mutually exclusive. PI3K pathway activation resulting from PTEN loss or PIK3CA mutations may lead to drug resistance to lapatinib and trastuzumab ( http://ClinicalTrials.gov number, NCT00338247 ).
    Type of Medium: Online Resource
    ISSN: 1471-2407
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2011
    detail.hit.zdb_id: 2041352-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...